Cuban delegation in SVG to introduce diabetes fighting drug

A delegation comprising two specialists is now in St Vincent and the Grenadines (SVG) to introduce the drug Heberprot-P, which is expected to reduce the incidence of amputations that are directly related to diabetes.{{more}}

The delegation, from the Republic of Cuba, arrived yesterday, March 19 and includes Dr Eberto Carrazana Peinado, angiologist, vascular surgeon and Ing Virgina Greenidge Smith, sales manager HEBER BIOTEC SA.

While in state the group is scheduled to make courtesy calls on Prime Minister Dr Ralph Gonsalves; Minister of Health, Wellness and the Environment Clayton Burgin; and Minister of Foreign Affairs Camillo Gonsalves. Further, the group will introduce the drug to officials from the Ministry of Health and make site visits to the Milton Cato Memorial Hospital and other health institutions.

Heberprot-P is the brand name of a drug developed by scientists at the Centre for Genetic Engineering and Biotechnology (CIGB) in Cuba as a cure for diabetic foot ulcer. It has been found to “promote granulation and healing in advanced diabetic foot ulcers.” Heberprot-P is indicated for the treatment of poor prognosis of deep, extensive, and terminal DFU not responding to comprehensive and/or extensive conventional methods, particularly in grades 3, 4 and 5 of Wagner’s Classification, with average ulcer size bigger than 2cm2, of both neuropathic and ischemic etiology with high risk amputation.